Clinical Trial

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-16.
Trial Details
NCT Number NCT07483307
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER+ Breast Cancer, Lobular Breast Carcinoma
Enrollment 176 participants
Start Date 2026-03-13
Primary Completion 2030-03-13 (estimated)
Study Completion 2030-03-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-04